Table 3 Medical therapy at baseline and follow-up
| Â | Baseline | Follow-up | ||||
|---|---|---|---|---|---|---|
Event (+) (n = 40) | Event (−) (n = 200) | P value | Event (+) (n = 40) | Event (−) (n = 200) | P value | |
Aspirin, n (%) | 39 (98) | 199 (99) | 0.28 | 40 (100) | 199 (99) | 0.55 |
Calcium-channel blocker, n (%) | 19 (48) | 103 (52) | 0.64 | 20 (50) | 110 (55) | 0.56 |
Beta-blocker, n (%) | 18 (45) | 104 (52) | 0.42 | 15 (38) | 104 (52) | 0.09 |
ACE inhibitor or ARB, n (%) | 19 (48) | 104 (52) | 0.60 | 21 (53) | 109 (55) | 0.82 |
Statin, n (%) | 20 (50) | 137 (69) | 0.03 | 34 (85) | 175 (88) | 0.67 |
Sulfonylurea, n (%) | 4 (10) | 13 (7) | 0.45 | 4 (10) | 13 (7) | 0.45 |
DPP-4 inhibitor, n (%) | 3 (8) | 24 (12) | 0.39 | 4 (10) | 24 (12) | 0.71 |
Metformin, n (%) | 3 (8) | 12 (6) | 0.73 | 3 (8) | 12 (6) | 0.73 |
Pioglitazone, n (%) | 1 (3) | 5 (3) | 1.00 | 1 (3) | 5 (3) | 1.00 |
Glinide, n (%) | 2 (5) | 7 (4) | 0.66 | 2 (5) | 6 (3) | 0.54 |
Alpha-glucosidase inhibitor, n (%) | 5 (13) | 11 (6) | 0.14 | 4 (10) | 9 (5) | 0.20 |
Insulin, n (%) | 4 (10) | 7 (4) | 0.11 | 4 (10) | 7 (4) | 0.11 |